The response deadline has passed. Review the details for future reference or to track similar opportunities.
The Department of Health and Human Services is procuring the synthesis of two specific chemical compounds for a Janus kinase 2 (JAK2) enzyme project aimed at evaluating their potential in brain cancer treatments. The compounds must be synthesized to a purity of 95% and delivered to the National Center for Advancing Translational Sciences (NCATS) within two months of the approved order.
The contractor will synthesize two specified compounds required for evaluation in brain cancer models, ensuring they meet a purity requirement of 95%.
Special Notice – Notice of Intent to Sole Source SOLICITATION NUMBER: 75N98026Q00251 TITLE: Preparation of chemical compounds needed for a Janus kinase 2 (JAK2) enzyme project . PRIMARY
POINT OF CONTACT: Jaddua Johnston [email protected] Phone: 240-569-0006 INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The compounds described below are needed for evaluation in brain cancer models in assay models at NCATS. They will allow us to determine the compound targets and provide insight into the specificity for brain cancer cells. NORTH AMERICAN INDUSTRY SYSTEM (NAICS) CODE and SET ASIDE STATUS NAICS code 325199 All Other Basic Organic Chemical Manufacturing @ 1250. This acquisition is NOT set aside for small businesses. REGULATORY AUTHORITY This acquisition will be conducted using FAR Part 12 – Acquisition of Commercial Items in conjunction with FAR Part 13 – Simplified Acquisition Procedures, as applicable. The resultant contract will include all appropriate provisions and clauses in effect through the current Federal Acquisition Circular (FAC). STATUTORY AUTHORITY This acquisition is being conducted under the authority of: FAR 6.302-1 – Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency
Requirements (41 U.S.C. 3304(a)(1)) DESCRIPTION OF REQUIREMENT: PURPOSE AND
OBJECTIVES: JAK2 inhibitors are medications that block the activity of the Janus kinase 2 (JAK2) enzyme, which is involved in signaling pathways related to inflammation and immune response. These inhibitors are used to treat various conditions, including some cancers and inflammatory diseases like rheumatoid arthritis and atopic dermatitis. We have discovered a compound that targets brain cancer cells and we require the synthesis of it an analog for evaluation in various brain-cancer cell targeted assays. These two compounds will be evaluated for their potential for treatment in brain cancer. - (1) 4-amino-N,N-dicyclopropyl-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; and - (2) N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide.
Period of Performance: Two months after receipt of approved order.
Get matched to contracts like this daily
Free AI-powered contract matching for your business.